Union Suit Claims Warner Chilcott Schemed to Stall Generics

A class action suit brought by a Pennsylvania-based union claims Warner Chilcott schemed a pay-for-delay deal with generic competitors to maintain a market for its contraceptive drug Loestrin 24 FE while it fights to cement a 16-year patent hold on a weaker, follow-on version.
Generic Line